Agenus

Agenus

An immuno-oncology company developing treatments for cancer

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

December 1, 2020
Agenus launches phase 2 trial expansion in Colon Cancer for AGEN1181 in Combination with BalstilimabNew objective response in colon cancer triggers trial expansion.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Agenus funding round, August 2009
9,350,000
August 4, 2009
1 Result
Results per page:
Page 1 of 1

Products

Product
Launch date
Industry
Website
AGEN2373
7 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Adam Hirsh

Employee

Alex Faylond

Employee

Bob Durham

Employee

Celena Toon

Employee

Christian Cortis

Employee

Christopher Clarke

Employee

Elben Guimaraes

Employee

Jacob Kung

Employee

Mike Klein

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
December 1, 2020
BioSpace
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the expansion of a Phase 2 trial into colon cancer based on a new objective clinical response in a colorectal cancer patient in addition to a significant tumor reduction of 27% and biomarker reduction observed i

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.